

Anthrax Vaccine Work Group

**David S. Stephens, MD, FIDSA
ACIP Anthrax Vaccine Work Group**

**Advisory Committee for
Immunization Practices
February 27, 2019**

ACIP Anthrax Work Group Members

ACIP Members: David Stephens, Chair; Robert L. Atmar; Sharon Frey

Ex Officio Members: Judy Hewitt (NIH); Amanda Zarrabian (BARDA); Alexandra Worobec (FDA); Eric Deussing (DOD); Kim Taylor (NIH); Chia-Wei Tsai (BARDA); Julianne Clifford (FDA)

Liaison Representatives: Richard Beigi (ACOG); Kathleen Neuzil (IDSA); James Campbell (AAP); Matthew Zahn (NACCHO)

Invited Consultants: Wendy Keitel; Arthur Friedlander; Phillip Pittman; Andy Pavia; Stacy Hall

CDC: William Bower, Lead

Anthrax Vaccine Work Group Activities

❑ Reconvened in March 2017

❑ Purpose

- The US government stockpiles medical countermeasures, including anthrax vaccine and CDC provides guidance for vaccine use and other aspects of preparedness **should there be a wide-area release of *Bacillus anthracis* spores**
- The work group considered the body of evidence since last review in 2010 for policy changes to optimize the use of anthrax vaccine for use prior to and following a wide-area release of *Bacillus anthracis* spores

Today's Session

1. **Informational session on use of new anthrax vaccine, AV7909, for post-exposure prophylaxis (PEP)**
2. **Policy vote on a change to the pre-exposure prophylaxis (PrEP) booster dose interval for persons who are not at current high risk of exposure to anthrax**

ACIP Anthrax Work Group Status

- ❑ **ACIP Anthrax Work Group will stand down after the MMWR policy updated is published**
- ❑ **We anticipate activating the work group again in 2021-22 to review:**
 - AV709 phase 2 and 3 that are currently in progress or planned
 - Data on booster dose intervals of >3 years for PrEP